Maravai Lifesciences Holdings, Inc.MRVI

NasdaqHealthcarePharmaceutical Preparations
Price (close)
$7.65
Market cap
$1.1B
P/E
—
Revenue (TTM)
$208.8M
Net income
-$77.4M
Dividend yield
—
1-year total return
184.4%
Net margin
-37.1%
Revenue growth
-5.0%
Debt / equity
0.72x

What Maravai Lifesciences Holdings, Inc. does.

Maravai LifeSciences Holdings, Inc. (also referred to in this document as “Maravai,” “we,” “us,” “our” or “the Company”) is a life sciences company providing critical products and services to enable the development of drugs, therapeutics, vaccines, and diagnostics, and support research on human disease. Our customers include biopharmaceutical companies, emerging biotech firms, life science research organizations, academic research institutions and diagnostics companies.

We operate and report our business in two segments – TriLink, formerly referred to as Nucleic Acid Production, and Cygnus, formerly referred to as Biologics Safety Testing.

During fiscal year 2025, we renamed our reportable segments from Nucleic Acid Production and Biologics Safety Testing to TriLink and Cygnus, respectively. This change reflects updated segment naming to better align with our internal brand and operating terminology. There were no changes to the composition of our reportable segments, the nature of the products and services offered, or the manner in which the chief operating decision maker (“CODM”) evaluates the Company’s operating performance or allocates resources.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$284.1M$799.2M$883.0M$288.9M$259.2M$185.7M
Net income$89.0M$182.0M$220.2M-$119.0M-$144.8M-$130.8M
Free cash flow$126.8M$353.7M$518.9M$60.7M-$22.2M-$70.7M

More on MRVI.

Figures from Maravai Lifesciences Holdings, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.